Evidence map›Paper›PMID 39656808›Full record

Trial reportThe Journal of infectious diseases2025

Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation.

Jaiprasath Sachithanandham, Julia Leep-Lazar, Jeffrey Quinn, Kenneth Bowden, Prasanthy Balasubramaniam, Kathleen Ward, Ruy M Ribeiro, Mark S Sulkowski, Ashwin Balagopal

Registry-linked trialAbstract readClinical Trial, Phase IVRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02938013 (deLIVER), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02938013 phase4completednot on this map

deLIVER: Direct Acting Antiviral Effects on the Liver

TypeinterventionalSponsorJohns Hopkins UniversityRan2017 to 2020Enrolled15ConditionsHCV Coinfection, Liver Disease, HIVArmsSofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX], Sofosbuvir/Velpatasvir (SOF/VEL)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jaiprasath SachithanandhamW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Public Health, Baltimore, Maryland.
Julia Leep-LazarLewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.
Jeffrey QuinnDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.
Kenneth BowdenApplied Physics Laboratory, Johns Hopkins University, Laurel, Maryland.
Prasanthy BalasubramaniamDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.
Kathleen WardDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.
Ruy M RibeiroTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico.
Mark S SulkowskiDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.
Ashwin BalagopalDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.ORCID 0000-0002-6143-3104

Funding

Management/Hepatitis C/HIV-infected and Uninfected IDU'sR01DA016065 · JOHNS HOPKINS UNIVERSITY · 2003 to 2005
$1.6M
NIH: Spatial Models of Intrahepatic Hepatitis Virus Propagation in HumansR01AI116868 · TRIAD NATIONAL SECURITY, LLC · 2025 to 2025
$867k
NIAID NIH HHS R01 AI116868NIAID NIH HHS R56 AI138810NIDA NIH HHS K24 DA034621NIDA NIH HHS R01 DA016065
6 · The paper itself

Abstract

backgroundHepatitis C virus (HCV) infects nearly one-fourth of people with human immunodeficiency virus (HIV). The role of direct-acting antivirals (DAAs) on immune activation in people with HIV (PWH) and HCV is poorly understood.

methodsWe quantified plasma HCV RNA and CXCL10 in persons with HCV monoinfection versus HIV/HCV coinfection receiving sofosbuvir-velpatasvir. Single-cell laser capture microdissection was applied to liver biopsies obtained before and within 4-7 days of DAA initiation to estimate HCV clearance and changes in interferon-stimulated genes (ISGs).

resultsWe enrolled 10 people with chronic genotype 1a HCV: 5 were PWH with ART-suppressed viremia and CD4+ T cell counts >200 cells/µL. First- and second-phase plasma HCV RNA kinetics were not different between groups. Median (min-max) proportions of infected hepatocytes at biopsy 1 were 0.06 (0.01-0.59) in HCV monoinfection and 0.21 (0.04-0.87) in HIV/HCV coinfection and did not differ. Participants had lower intracellular HCV RNA levels at biopsy 2. CXCL10 levels declined in both groups but were higher in coinfection than in monoinfection even at the end of treatment. The proportion of cells expressing ISGs diminished in monoinfection but increased in coinfection.

conclusionsWhereas DAAs rapidly cleared intrahepatic HCV in both groups, immune activation was slower to diminish in PWH. Residual immune activation in PWH warrants further exploration. Clinical Trials Registration. NCT02938013.

Indexed as

Antiviral AgentsHepacivirusHepatitis CHepatitis C, ChronicHIV InfectionsLiverAdultBenzimidazolesBenzopyransCarbamatesChemokine CXCL10CoinfectionFemaleHeterocyclic Compounds, 4 or More RingsHumansMaleAntiviral AgentsBenzimidazolesBenzopyransCarbamatesChemokine CXCL10CXCL10 protein, humanHeterocyclic Compounds, 4 or More RingsRNA, ViralSofosbuvirvelpatasvirdirect-acting antiviralsHIV/HCV coinfectionimmune activationsingle-cell laser capture microdissectionviral kinetics

Identifiers

PMID39656808
PMCPMC12837052

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.